Affordable Access

deepdyve-link
Publisher Website

MRI pattern in asymptomatic natalizumab-associated PML.

Authors
  • Wattjes, Mike P1
  • Vennegoor, Anke2
  • Steenwijk, Martijn D1
  • de Vos, Marlieke1
  • Killestein, Joep2
  • van Oosten, Bob W2
  • Mostert, Jop3
  • Siepman, Dorine A4
  • Moll, Wiebe5
  • van Golde, Alex E L6
  • Frequin, Stephan T F M7
  • Richert, Nancy D8
  • Barkhof, Frederik1
  • 1 Department of Radiology and Nuclear Medicine, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. , (Netherlands)
  • 2 Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. , (Netherlands)
  • 3 Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands. , (Netherlands)
  • 4 Department of Neurology, Erasmus MC, University Medical Center Rotterdam, MS Center, Rotterdam, The Netherlands. , (Netherlands)
  • 5 Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands. , (Netherlands)
  • 6 Department of Neurology, GT Hospital Almelo, Almelo, The Netherlands. , (Netherlands)
  • 7 Department of Neurology, St. Antonius Hospital, Nieuwegein, The Netherlands. , (Netherlands)
  • 8 Multiple Sclerosis Clinical Development Group, Biogen Idec, Cambridge, Massachusetts, USA.
Type
Published Article
Journal
Journal of Neurology Neurosurgery & Psychiatry
Publisher
BMJ
Publication Date
Jul 01, 2015
Volume
86
Issue
7
Pages
793–798
Identifiers
DOI: 10.1136/jnnp-2014-308630
PMID: 25205744
Source
Medline
Keywords
License
Unknown

Abstract

Asymptomatic natalizumab-associated PML manifestations on MRI show a rather localised disease, frequently located in the frontal lobes, affecting the cortical grey matter and adjacent juxtacortical white matter. Awareness of this lesion pattern facilitates an earlier diagnosis of natalizumab-associated PML in an asymptomatic stage associated with a more favourable prognosis.

Report this publication

Statistics

Seen <100 times